(Total Views: 531)
Posted On: 05/16/2017 8:05:35 PM
Post# of 72446
Prurisol: Efficacy seems to be dose-related in Phase 2a.
In the ITT population where >= 2-point improvement in IGA was observed at week 12, 25% was in the 200 mg arm, 10.7% was in the 100 mg arm, 10.3% was in the 50 mg arm.
In the PP population where >= 2-point improvement in IGA was observed at week 12, 35% was in the 200 mg arm, 13% was in the 100 mg arm, 15% was in the 50 mg arm.
Dosage in Phase 2b will increase to 300 mg and 400 mg, so efficacy should improve.
In the ITT population where >= 2-point improvement in IGA was observed at week 12, 25% was in the 200 mg arm, 10.7% was in the 100 mg arm, 10.3% was in the 50 mg arm.
In the PP population where >= 2-point improvement in IGA was observed at week 12, 35% was in the 200 mg arm, 13% was in the 100 mg arm, 15% was in the 50 mg arm.
Dosage in Phase 2b will increase to 300 mg and 400 mg, so efficacy should improve.
(3)
(0)
